Keytruda Approved for Advanced or Recurrent Cervical Cancer in Japan
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On September 26, 2022, MSD K.K. announced that the anti-PD-1 therapy Keytruda (Pembrolizumab) has received approval in Japan for an expanded indication: the treatment of patients with advanced or recurrent cervical cancer.
Clinical Evidence: KEYNOTE-826 Trial
The approval is supported by the results of the KEYNOTE-826 Phase 3 clinical trial, an international, multicenter, randomized study involving 617 patients with persistent, recurrent, or metastatic cervical cancer who had not received prior systemic chemotherapy.
Participants were randomized to receive:
- Keytruda + Chemotherapy (with or without Bevacizumab).
- Placebo + Chemotherapy (with or without Bevacizumab).
Key Survival Results
The trial demonstrated that the addition of Keytruda to standard chemotherapy significantly improved outcomes:
- Overall Survival (OS): Patients in the Keytruda group experienced a statistically significant prolongation of life compared to the placebo group.
- Progression-Free Survival (PFS): Keytruda also significantly extended the time patients lived without their disease worsening.
Future Outlook
MSD K.K. emphasized its commitment to developing innovative oncology treatments to meet the unmet needs of patients and healthcare professionals in Japan and globally.
Source: MSD K.K. Press Release - Keytruda Approval for Cervical Cancer
#CervicalCancer #Keytruda #Pembrolizumab #KEYNOTE826 #Immunotherapy #CancerResearch #JapanMedicine
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4